Drug Profile
Ribociclib - Novartis Oncology
Alternative Names: Kisqali; LEE-011; LEE-011ALatest Information Update: 11 Apr 2024
Price :
$50
*
At a glance
- Originator Astex Therapeutics; Mount Sinai Health System
- Developer Array BioPharma; Cedars-Sinai Medical Center; Cincinnati Children's Hospital Medical Center; Cliniques Universitaires Saint Luc; Dana-Farber Cancer Institute; Georgetown University; Gynecologic Oncology Group; Hadassah Medical Organization; Mayo Clinic; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); National Taiwan University Hospital; Novartis; Novartis Oncology; Roswell Park Cancer Institute; Seagen; SOLTI Breast Cancer Research Group; St Josephs Hospital and Medical Center; Thomas Jefferson University; UNICANCER; University of Texas M. D. Anderson Cancer Center; University of Texas Southwestern Medical Center; Virginia Mason Research Center
- Class Amides; Aminopyridines; Antineoplastics; Piperazines; Pyrimidines; Pyrroles; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors; Oligodendrocyte transcription factor 2 inhibitors; Type 3 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer
- Phase II Cancer; Malignant melanoma; Neuroendocrine tumours; Ovarian cancer; Peritoneal cancer
- Phase I/II Liposarcoma; Neuroblastoma; Pancreatic cancer; Triple negative breast cancer
- Phase I Glioma; Medulloblastoma; Rhabdoid tumour; Rhabdomyosarcoma
- No development reported Lymphoma; Non-small cell lung cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer
- Discontinued Endometrial cancer; Fallopian tube cancer; Head and neck cancer; Liver cancer; Meningioma; Prostate cancer; Teratoma
Most Recent Events
- 10 Apr 2024 Phase-III clinical trials in Breast cancer (Combination therapy, Adjuvant therapy, Early-stage disease) in Australia (PO) (NCT05827081)
- 21 Mar 2024 Updated efficacy data from the phase III NATALEE trial in Breast Cancer released by Novartis
- 27 Feb 2024 Preregistration for Breast cancer (Second-line therapy or greater, Adjuvant therapy) in USA (PO) (Novartis pipeline, February 2024).